New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 10, 2013
07:04 EDTCCXIChemoCentryx says interim data support continued dosing in Phase II study
ChemoCentryx announced interim data from an ongoing Phase II study in patients with diabetic nephropathy, also known as diabetic kidney disease, with CCX140. CCX140 is an inhibitor of the chemokine receptor known as CCR2, and the drug candidate is wholly owned by the company. Examining data through the first 12 weeks of dosing in the ongoing 52 week trial, in which CCX140 is added on top of the standard of care for diabetic nephropathy patients, the drug candidate appears well-tolerated in the patient population to date. The safety observations were consistent with a concurrent analysis by the company's independent safety data monitoring committee, which independently assessed the interim data and recommended no changes to the ongoing study protocol. In addition, data also showed that patients treated with 5 mg CCX140 once daily experienced a statistically significant reduction of protein in the urine, or proteinuria, as measured by Urinary Albumin Creatinine Ratio versus those patients receiving only the standard of care, following two weeks of treatment, with continuing downward trends in UACR observed following 8-weeks and 12-weeks of treatment with CCX140. In pre-specified analyses of subsets of patients in the study, greater reductions in proteinuria were observed, including decreases of approximately 30% in UACR in the CCX140 groups versus those patients only on background medications. The company indicated that the data support the continued progress of full 52 weeks of dosing in the Phase II trial as planned. Data from the full study are expected in the second half of 2014, which will continue to monitor proteinuria as well as assess additional markers related to kidney function, including serum creatinine and estimated glomerular filtration rate, measures which historically take longer to be detected in clinical trials.
News For CCXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
08:39 EDTCCXIChemoCentryx reports CCX507 well tolerated, effective in Phase I study
Subscribe for More Information
October 20, 2014
08:37 EDTCCXIChemoCentryx releases Phase III SHIELD 4 clinical results
ChemoCentryx reported data from the Phase III SHIELD 4 clinical trial in Crohn's disease with vercirnon, an inhibitor of the chemokine receptor known as CCR9. Data showed that patients experienced improved response and remission rates when taking a higher dose of vercirnon. There was no evidence of higher gastrointestinal, hepatic, or cardiovascular adverse events with the twice daily group compared to the once daily group. Thomas J. Schall, Ph.D., president and CEO stated, "These SHIELD 4 data are consistent with our earlier positive PROTECT-1 study data. As with PROTECT-1, the data indicate that vercirnon is safe and well tolerated in patients with Crohn's disease, and there is a dose-dependent improvement in symptoms in the observed patient population in SHIELD 4. The Phase III drug CCX282/vercirnon, in addition to our second-generation, Phase II-ready CCR9 inhibitor, CCX507, provide a strong complement of drugs in our CCR9 program for which we intend to find a strategic partner."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use